GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Investments And Advances

CGON (CG Oncology) Investments And Advances : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is CG Oncology Investments And Advances?

CG Oncology's Investments And Advances for the quarter that ended in Dec. 2024 was $0.00 Mil.

CG Oncology Investments And Advances Historical Data

The historical data trend for CG Oncology's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CG Oncology Investments And Advances Chart

CG Oncology Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Investments And Advances
- - - -

CG Oncology Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Investments And Advances Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CG Oncology Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

CG Oncology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CG Oncology Inc (NAS:CGON) » Definitions » Investments And Advances
Comparable Companies
HRMY AGIO ARQT IDYA TVTX ARWR JANX IRON EWTX NAMS VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
400 Spectrum Center Drive, Suite 2040, Irvine, CA, USA, 92618
Website
https://www.cgoncology.com
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.